1 / 28

Internal use only

Agendia Summary of Results. Internal use only. Why update the Summary of Results?. www.agendia.com. Inclusion of new prospective trial data: Level 1A MINDACT data Late Recurrence (20yr) Low Risk result from STO-3 study

pjosephine
Télécharger la présentation

Internal use only

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Agendia Summary of Results Internal use only

  2. Why update the Summary of Results? www.agendia.com • Inclusion of new prospective trial data: • Level 1A MINDACT data • Late Recurrence (20yr) Low Risk result from STO-3 study • Improved usability of the Summary of Results in your discussions with patients • Provision of additional clinically meaningful information • Incorporation of feedback from consultations with physicians and patients to improve the Summary of Results

  3. Introducing the new Summary of Results To: From: www.agendia.com

  4. What has changed? www.agendia.com • Includes: • Treated data (MINDACT, Cardoso et al., 2016) • Untreated data (Buyse et al., 2006) • Late Recurrence (20yr) Low Risk (LRLR) result for applicable patients (STO-3, Esserman et al., 2017) • Clinical risk algorithm (modified Adjuvant!Online) • Demonstrates 5 and 10-year risk of recurrence more simply and succinctly • Content and format updated and localized to be more user-friendly for both physicians and patients in the EU • Refined based on feedback from customers and leading KOLs including • Prof. Fatima Cardoso • Prof. Martine Piccart • NOTE: The official MammaPrint and BluePrint Results Report will retain the same data and appearance. An update is in progress.

  5. Summary of Results: Overview

  6. Summary of Results: OverviewPage 1 Supporting data from prospective clinical trials and summary of patient-specific MammaPrint and BluePrint results www.agendia.com • Easy-to-read MammaPrint and BluePrint (if applicable) results • MammaPrint Risk of Recurrence Result • MammaPrint Index (MPI) • BluePrint Molecular Subtype Result (when the BluePrint test has been ordered) • Prognostic validation data for MammaPrint on untreated patients • 302 patients from the TRANSBIG study • Clinical utility data for MammaPrint on treated patients (treatment impact) • 6,693 patients from the MINDACT trial

  7. Summary of Results: OverviewPage 2 Clinical risk assessment reference table and BluePrint molecular subtyping * www.agendia.com • Clinical risk algorithm (modified Adjuvant!Online) • Reproduction of algorithm used to assess clinical risk for patients in MINDACT • Information on functional molecular subtyping with BluePrint and pCR rate with neoadjuvant chemotherapy NOTE:*Only included when BluePrint test has been ordered • Can support discussions with patients regarding their treatment management decision

  8. Summary of Results: OverviewPage 3 MammaPrint Late Recurrence (20yr) Low Risk Result www.agendia.com • If a patient has an MPI of > +0.355 they are Late Recurrence (20yr) Low Risk (LRLR) • This subgroup identifies patients with an excellent 20-year survival with limited or no hormone therapy • If applicable, LRLR Summary of Results will be added to the report as a third page • It contains: • Data from the STO-3 trial • 20-year outcome data for patients with limited and no hormone therapy

  9. Summary of ResultsExamples and in-depth review

  10. MammaPrint Low Risk

  11. Summary of ResultsMammaPrint Low Risk, BluePrint Luminal-Type (A), LRLR 7 9 1 2 11 3 4 10 5 12 8 6 www.agendia.com

  12. MammaPrint Low RiskPage 1

  13. 1 2 4 3

  14. 5 6

  15. Page 2

  16. 7

  17. 8

  18. Late Recurrence (20yr) Low RiskPage 3

  19. 9 11 10

  20. 12

  21. MammaPrint High Risk

  22. MammaPrint High RiskPage 1

  23. 1 2 4 3

  24. 5 6

  25. Summary of Results Resources and Support

  26. Resources and Support Please remember to download the new Summary of Results in addition to your official MammaPrint and BluePrint Results Report. For more information please visit: www.agendia.com/healthcare-professionals/row-summary-of-results Further questions? Please contact your local Agendia representative or our Customer Service team by calling +31 20 462 1510, or by email at customerservice@agendia.com

  27. Thank you for your attention

  28. For more information about Agendia and our products visit www.agendia.com or contact: T: +31 (0)20 462 1510 E: customerservice@agendia.com Follow us on Twitter | LinkedIn | Facebook www.agendia.com M-ROW-199-V1 (2018JUL)

More Related